Amylin and JDRF to investigate the feasibility of a fixed-dose combination of Symlin and insulin for Type I diabetes

Amylin Pharmaceuticals Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

JDRF

U.S. / Non-Profit or Major Disease Foundation

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced